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Abstract
Background:  Despite governmental and private efforts on providing malaria control, this disease
continues to be a major health threat. Thus, innovative strategies are needed to reduce disease burden.
The malaria vectors, through the injection of saliva into the host skin, play important role on disease
transmission and may influence malaria morbidity. This study describes the humoral immune response
against Anopheles (An.) darlingi saliva in volunteers from the Brazilian Amazon and addresses the association
between levels of specific antibodies and clinical presentation of Plasmodium (P.) vivax infection.
Methods: Adult volunteers from communities in the Rondônia State, Brazil, were screened in order to
assess the presence of P. vivax infection by light microscopy and nested PCR. Non-infected volunteers and
individuals with symptomatic or symptomless infection were randomly selected and plasma collected. An.
darlingi salivary gland sonicates (SGS) were prepared and used to measure anti-saliva antibody levels.
Plasma interleukin (IL)-10 and interferon (IFN)-γ levels were also estimated and correlated to anti-SGS
levels.
Results: Individuals infected with P. vivax presented higher levels of anti-SGS than non-infected individuals
and antibody levels could discriminate infection. Furthermore, anti-saliva antibody measurement was also
useful to distinguish asymptomatic infection from non-infection, with a high likelihood ratio. Interestingly,
individuals with asymptomatic parasitaemia presented higher titers of anti-SGS and lower IFN-γ/IL-10 ratio
than symptomatic ones. In P. vivax-infected asymptomatic individuals, the IFN-γ/IL-10 ratio was inversely
correlated to anti-SGS titers, although not for while in symptomatic volunteers.
Conclusion: The estimation of anti-An. darlingi antibody levels can indicate the probable P. vivax infection
status and also could serve as a marker of disease severity in this region of Brazilian Amazon.
Published: 5 June 2009
Malaria Journal 2009, 8:121 doi:10.1186/1475-2875-8-121
Received: 6 April 2009
Accepted: 5 June 2009
This article is available from: http://www.malariajournal.com/content/8/1/121
© 2009 Andrade et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2009, 8:121 http://www.malariajournal.com/content/8/1/121
Page 2 of 9
(page number not for citation purposes)
Background
Malaria continues to be one of the most serious public
health problems worldwide, exacting a huge impact on
human wellbeing, mainly in tropical and subtropical
countries. A better understanding of the interactions
between the host, the vector and the parasite could be val-
uable to indicate future strategies. In endemic regions, res-
idents are frequently bitten by both uninfected and
infected mosquitoes. There is also a progressive acquisi-
tion of immunity, leading to a decreased number of
malaria clinical attacks related to increasing age and time
residing in the endemic area [1,2]. Within the Brazilian
Amazon, and mainly in riverine communities, the preva-
lence of asymptomatic malaria infection seems to be four
to five times greater than the symptomatic infection [3-5].
Malaria clinical immunity has already been described in
both Plasmodium (P.) falciparum [6] and Plasmodium (P.)
vivax [7] infections and it seems to be related to higher tit-
ers of anti-Plasmodium antibodies [8]. On the other hand,
anti-parasite response might not be the unique determi-
nant of the occurrence of symptomless malaria, as asymp-
tomatic patients maintain parasitaemia at low levels in
addition to controlling the clinical symptoms [9]. Such
asymptomatic carriers have developed just enough immu-
nity to protect them from malarial illness but not from
malarial infection. Regardless these facts, the specific
mechanisms that underlie the occurrence of clinical
immunity against the Plasmodium  are not well under-
stood.
In this scenario, the anopheline vector could play signifi-
cant role in malaria clinical severity. Mosquito bites can
induce immediate, delayed, and systemic hypersensitivity
reactions in hosts [10]. Moreover, pre-exposure to the vec-
tor saliva may create an inhospitable environment for the
establishment of the parasites transmitted by these
insects. Mice repeatedly exposed to bites from uninfected
Anopheles (An.) stephensi increase a pro-inflammatory T
helper 1 biased response that limits P. yoelii infection [11].
In humans it has been shown that An. gambiae saliva is
immunogenic for travelers transiently exposed to bites in
African endemic areas [12], with the development of spe-
cific IgG and IgM antibodies. Specific anti-An. gambiae
saliva IgG antibodies were also detected in young children
from a seasonal malaria transmission region in Senegal,
and antibody levels were higher in patients who devel-
oped clinical malaria episodes, suggesting that the estima-
tion of humoral response to Anopheles salivary antigens
can serve as potential marker for the risk of malaria [13].
Moreover, anti-An. dirus salivary protein antibodies occur
predominantly in patients with acute P. falciparum or P.
vivax malaria, whereas people from non-malarious areas
do not carry such antibodies [14]. Little is known about
anti-saliva humoral responses in other endemic areas,
such as Latin America. In addition, the host response
against the most widespread malaria vector in America,
An. darlingi, is poorly explored. The objective of the
present work was to measure the anti-saliva IgG responses
against An. darlingi mosquitoes in the Brazilian Amazon
and to evaluate the association of antibody levels with dif-
ferent clinical presentations of P. vivax infections.
Methods
Study localities
A cross-sectional study investigating determinant factors
for asymptomatic P. vivax malaria was performed during
2007 (June to August) in Buritis (10°12'43" S; 63°49'44"
W), a recent urbanized municipality, and Demarcação
(8°10'04.12" S; 62°46'52.33" W), a riverine community
of the Rondônia State, in the south-western part of Brazil-
ian Amazon. In general, Rondônia has a flat topography,
with an average elevation of 300 m above sea level. The
climate is tropical, with a long rainy season from January
till May. It is argued that the environmental changes
caused by deforestation have favored the main malaria
vector in Brazil An. darlingi [15]. Within the regions stud-
ied here, the malaria transmission is unstable, with
increased number of cases being detected annually
between April to September, and the risk of infection is
moderate to high [16], with an Annual Parasite Incidence
of 77.5 per 1,000 inhabitants in 2005 [17]. In the Brazil-
ian Amazon, P. vivax accounts for the majority of malaria
cases, while P. falciparum infection prevalence is 23.7%
[17]. In addition, infection with P. malariae achieves 10%
in Rondônia [18].
Volunteers
Active and passive malaria case detections were performed
in the two communities studied. A small laboratory with
necessary facilities was built inside the main centers for
malaria diagnosis in Buritis and Demarcação. These diag-
nostic centers are linked to the Brazilian National Founda-
tion of Health (FUNASA), responsible for malaria control
in the Brazilian Amazon. Active case detection was made
by visiting residences in regions pointed by the local
health authorities as major areas of disease transmission.
The individuals were examined and interviewed by a
trained physician, and blood samples were collected for
serological experiments. The malaria diagnosis was per-
formed using two methods. First, patients were screened
by thick smear examination using field microscopy and
the parasitaemia (parasites/μL) was calculated in positive
cases. Further, nested PCR was performed in all whole
blood samples to confirm the diagnosis (as described
below). Two individuals presenting P. malariae infection
and 16 persons infected with P. falciparum were identified
and excluded from the study. Hence, all the volunteers
selected were negative for P. falciparum and/or P. malariae
infection by both microscopic examination and nested
PCR. Other exclusion criteria were chronic alcoholism,Malaria Journal 2009, 8:121 http://www.malariajournal.com/content/8/1/121
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severe chronic degenerative disease as well as HIV, HBV
and HCV infections. A total of 204 volunteers were used
in the study. All the positive cases were followed up for 30
days for the evaluation of malaria symptoms. Individuals
who were positive for P. vivax infection and remained
without fever (axilary temperature >37.8°C) and/or
chills, sweats, strong headaches, myalgia, nausea, vomit-
ing, jaundice, asthenia, and arthralgia for 30 days were
considered asymptomatic, while in the presence of any
listed symptom they were classified as symptomatic. The
volunteers were stratified in three different groups accord-
ing to the P. vivax malaria diagnosis and the clinical spec-
trum of the disease. Thus, 80 people were non-infected,
50 had asymptomatic infection and 74 were sympto-
matic. The baseline characteristics of the volunteers are
listed in the Table 1. Three volunteers from asymptomatic
infection group presented negative light microscopy
exam, but P. vivax DNA was amplified by nested PCR
(Table 1). This study was a part of the project approved by
the Ethical Committee of the São Lucas University,
Rondônia, Brazil, for the human subject protocol and is in
compliance with the Helsinki Declaration. All partici-
pants gave written informed consent before entering the
study.
Molecular malaria diagnosis
The molecular diagnosis of malaria infection was per-
formed using the nested PCR technique, based on the
Snounou protocols, with minimal alterations [19,20].
The target was the 18S rRNA gene, and genus- and species-
specific primers were used in the assay. Briefly, 300 μL of
whole blood collected on EDTA was prepared for DNA
extraction through the phenol-chloroform method fol-
lowed by precipitation with sodium acetate and ethanol.
The first PCR rDNA amplification was performed with
Plasmodium  genus-specific primers named PLU5 and
PLU6. Positive samples yielded a 1,200-bp fragment,
which served as template for the nested reaction. The
nested PCR amplification was performed with species-
specific primers for 30 cycles at annealing temperatures of
58°C for P. falciparum (Fal1 and Fal2 primers), and 65°C
for P. vivax (Viv1 and Viv2 primers) or P. malariae (Mal1
and Mal2 primers). The fragments obtained for P. vivax
were of 120 bp, whereas for P. falciparum and P. malariae
were 205 bp and 144 bp, respectively. The oligonucle-
otide sequences of each primer used are listed in Table 2.
The products were visualized in 2% agarose gel stained
with ethidium bromide. To control for cross-contamina-
tion, one uninfected blood sample was included for every
twelve samples processed. Fifteen percent of positive PCR
samples were re-tested to confirm the amplification of
plasmodial DNA. All the tests were performed and con-
firmed at the Centro de Pesquisas Gonçalo Moniz
(FIOCRUZ-BA).
Salivary Gland Sonicate (SGS) preparation
Salivary glands from field captured adult female An. dar-
lingi mosquitoes were dissected and transferred to 20 μL
Table 1: Baseline characteristics of the volunteers.
Plasmodium vivax current infection P value
Variable Non-infected Asymptomatic Symptomatic
(n = 80) (n = 50) (n = 74)
Age – years* 30 (23–44.5) 44.5 (34.5–51) 27.5 (21–37) 0.0341†
Malaria episodes referred* 13.5 (11–18) 17.5 (13–21) 7 (1–13) 0.0283†
Time residing in the area – years 0.0185‡
<2 25 (31.3%) 8 (16%) 31 (41.9%)
3–10 12 (15%) 12 (24%) 16 (21.6%)
>10 43 (53.7%) 30 (60%) 27 (36.5%)
Parasitaemia – parasites/μL < 0.0001‡
ND§ 80 (100%) 3 (6%) § 0
100–<500 0 44 (88%) 34 (45.9%)
500–<5,000 0 3 (6%) 5 (6.8%)
5,000–<50,000 0 0 30 (40.5%)
>50,000 0 0 5 (6.8%)
IgG anti-SGS – O.D.* 0.06 (0.04–0.09) 0.13 (0.08–0.26) 0.095 (0.07–0.14) < 0.0001†
Plasma IL-10 – pg/mL* 12.6 (7.4–19.2) 64.5 (7.3–86.0) 23.4 (9.5–58.4) NS†
Plasma IFN-γ – pg/mL* 14.2 (0–32.0) 44.0 (10.5–101.0) 75.5 (38.8–243.5) NS†
* Values plotted represent media and range
† Ordinal variables were compared between groups Kruskal-Wallis test with Dunn's multiple comparison test.
‡ Categorized variables were compared using chi-squared test. P values obtained in each test are plotted.
§ND: Six patients, out of 50 were negative for malaria infection by light microscopy, but were positive for P. vivax infection by nested PCR.
NS: Non significant.Malaria Journal 2009, 8:121 http://www.malariajournal.com/content/8/1/121
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of 10 mM HEPES pH 7.0, 0.15 mM NaCl in 1.5-mL poly-
propylene vials, usually in groups of 20 gland pairs. Sali-
vary glands were kept at -70°C until needed, when they
were disrupted by sonication using a Branson Sonifier 450
homogenizer (Branson, Danbury, CT). The homogenates
were centrifuged at 10,000 × g for 4 min and the superna-
tants were used for the experiments. Protein concentra-
tions were measured by the bicinchonic acid method
(BCA, Pierce, Rockford, Illinois, USA). As the salivary
glands used in this study were obtained from field cap-
tured mosquitoes, Plasmodium contamination needed to
be checked by nested PCR. Briefly, it was performed the
DNA extraction of a sample from the same SGS pool used
in the serological experiments using the Qiagen Genera-
tion Capture Card Kit (Cat. No. 159982; Qiagen, Santa
Clara, California, USA). Further, the nested PCR was per-
formed as described above, in duplicate samples. There
was no amplification of DNA in both duplicates (data not
shown).
Anti-An. darlingi saliva serology
Volunteer's sera were collected and kept at -70°C. Serolog-
ical tests of all samples were performed in a single experi-
ment, with duplicate samples. ELISA was performed as
described elsewhere [14]. Briefly, plates were coated with
An. darlingi salivary homogenate (SGS) equivalent to 1.5
μg/mL in carbonate buffer overnight at 4°C, then washed
with PBS/0.05% Tween and blocked with PBS/0.1%
Tween plus 0.05% BSA. Sera were diluted 1:100 with PBS/
0.05% Tween and incubated overnight at 4°C. After fur-
ther washings, the wells were incubated with alkaline
phosphatase-conjugated anti-human IgG (Sigma-Aldrich,
St. Louis, MO) at a 1:5,000 dilution. Following another
washing cycle, the color was developed with p-nitrophe-
nylphosphate. The reactions were blocked with NaOH
and read at 405 nm using Soft Max-Pro Software v5
(Molecular Devices Corporation, Sunnyvale, California,
USA) ELISA reader. The optical density (OD) values plot-
ted represent the means between each sample duplicate,
adjusted for the values from the blank wells.
Plasma cytokine measurement
Interleukin (IL)-10 and interferon (IFN)-γ plasma levels
were measured using de Cytometric Bead Array – CBA®
(BD Biosciences Pharmingen, San Diego, California,
USA) according to the manufacturer's protocol.
Statistical analysis
Data were analyzed using the GraphPad Prism 5.00®
(GraphPad Software Inc.). For the ordinal variables (age,
referred malaria episodes, IgG, IL-10 and IFN-γ serum lev-
els), differences between groups were calculated using the
non parametric Kruskal-Wallis test with Dunn's multiple
comparison post test. Chi-square test was used to com-
pare differences regarding categorized variables (Time
residing in the area and parasitaemia). Mann-Whitney test
was used to compare differences in IgG levels between
non-infected individuals and those with symptomatic or
asymptomatic P. vivax infection. This test was also used to
estimate significance in IFN-γ/IL-10 ratios from volunteers
with asymptomatic or symptomatic P. vivax infection. To
evaluate the cut off value of IgG anti-SGS predicting
malaria infection or asymptomatic infection, we per-
formed Receiver-operator characteristic (ROC) curves, cal-
culated the Area under curve (AUC), and then estimated
the likelihood ratio for the discrimination between the
conditions analyzed. Fine Lowess curves were plotted to
evidence the trend of the data presented in correlation
analyzes. Spearman test was used to verify the significance
in the correlations between cytokine levels and anti-SGS
levels. Differences were considered significant at P < 0.05.
Results and discussion
In an attempt to check if the measurement of anti-SGS
antibody levels could be a suitable method to estimate
natural exposure to P. vivax, anti-SGS values obtained
from non-infected individuals were compared to those
from either symptomatic or asymptomatic infected volun-
teers. As seen in Figure 1A, infected patients presented
higher levels of specific antibodies against An. darlingi sal-
ivary antigens than non-infected individuals. The variabil-
Table 2: Primers used in Nested PCR reactions.
Primer Oligonucleotide Sequence 5'-3' Base pairs
PLU5 CCTGTTGTTGCCTTAAACTTC 1,200
PLU6 TTAAAATTGTTGCAGTTAAAA
Fal1 TTAAACTGGTTTGGGAAAACCAAATATATT 205
Fal2 ACACAATGAACTCAATCATGACTACCCGTC
Viv1 CGCTTCTAGCTTAATCCACATAACTGATAC 120
Viv2 ACTTCCAAGCCGAAGCAAAGAAAGTCCTTA
Mal1 ATAACATAGTTGTACGTTAAGAATAACCGC 144
Mal2 AAAATTCCCATGCATAAAAAATTATACAAA
PLU: Plasmodium sp, Fal: Plasmodium falciparum, Viv: Plasmodium vivax, Mal: Plasmodium malariae.Malaria Journal 2009, 8:121 http://www.malariajournal.com/content/8/1/121
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ity probably indicates individual differences in exposure
to mosquito bites, even during the period of high malaria
transmission, when these data were collected. Previous
studies have also demonstrated a high variation in anti-
An. dirus saliva antibody titers [14].
A ROC curve was built to assess the best anti-SGS OD
value to discriminate P. vivax infection from the non-
infected condition. A cut-off point of 0.0855 OD dis-
played a likelihood ratio to be infected of 2.11 indicating
P. vivax infection (Figure 1B; AUC: 0.727; p < 0.0001).
These data suggest that evaluation of anti-saliva antibod-
ies could be a useful indicator to estimate exposure to P.
vivax in this endemic area. High anti-SGS antibody levels
were also proposed as putative biomarkers of exposure to
bites of An. stetephensi or An. gambiae and also of risk of P.
falciparum malaria [13]. In this study, besides suggesting
exposure to bites, high anti-An. darlingi saliva antibody
levels could also indicate exposure to P. vivax.
This work is the first to evaluate human immune response
against salivary components of An. darlingi, the most
widespread specie of Anopheles mosquitoes and the major
malaria vector in the Americas [21]. In areas with unstable
malaria transmission and moderate risk of infection, such
as the Brazilian Amazon, adults, instead of children are
largely affected by the disease. Hence, this study focused
investigation on the adult population from a Brazilian
endemic area.
Diagnosis of symptomatic malaria cases is routinely per-
formed in the endemic areas. A real challenge for diagno-
sis is to discriminate asymptomatic Plasmodium-infected
individuals from those with no malaria infection. Despite
presenting no clinical manifestations, asymptomatic Plas-
modium-infected individuals are able to transmit Plasmo-
dium to uninfected mosquitoes [22]. Thus, asymptomatic
persons could serve as important reservoirs, and the pos-
sibility of identifying them could be useful for malaria
control. Asymptomatic individuals presented higher anti-
SGS antibody levels than non-infected individuals (Figure
2A, p < 0.0001). A ROC curve to discriminate these two
clinical conditions showed that a cut-off value of 0.0935
OD, with a likelihood ratio of 3.03, indicated asympto-
matic infection (Figure 2B; AUC: 0.798; p = 0.0001). Con-
sidering solely the P. vivax infected patients,
asymptomatic individuals presented higher levels of anti-
SGS than symptomatic ones (Figure 3, p = 0.0009). Eval-
uation of antibodies against An. darlingi saliva may serve
as a marker of P. vivax asymptomatic infection in this Bra-
zilian malaria endemic area.
In order to explore immunopathological patterns in P.
vivax infection, the correlation between the anti-SGS anti-
body levels and the serological cytokine profile in asymp-
tomatic and symptomatic malaria patients was evaluated.
Volunteers with asymptomatic parasitaemia had a posi-
tive correlation between IL-10 and anti-SGS levels (Figure
4A. r = 0.50; p = 0.0002), but this finding was not seen in
symptomatic individuals (Figure 4B. r = 0.16; p = 0.17).
IFN-γ serum levels did not display significant correlation
with anti-saliva antibodies in either asymptomatic (Figure
4C. r = 0.25; p = 0.07) or symptomatic (Figure 4D. r =
Anti-saliva IgG serum levels according to malaria occurrence Figure 1
Anti-saliva IgG serum levels according to malaria 
occurrence. Serums were collected from non-infected indi-
viduals (n = 80), and from patients with P. vivax infection with 
or without symptoms (n = 124). An ELISA test was per-
formed to assess the IgG anti-An. darlingi SGS. (A) Box plot 
graphs of IgG serum levels from non-infected individuals and 
from patients with P. vivax infection. Lines of the boxes rep-
resent 75th percentile, median and 25th percentile of the indi-
vidual average OD values; whiskers represent the maximum 
and minimum values. Differences between groups were 
tested using Mann Whitney test. (B) ROC curve evaluating 
the threshold value of anti-SGS that separates non-infected 
individuals from P. vivax infection. Area under curve (AUC) 
calculated, together with the cut off value, which presents 
the higher likelihood ratio, and p values are plotted.
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0.12; p = 0.29) patients. Moreover, a significant negative
correlation between the IFN-γ/IL-10 ratio and anti-SGS
levels in asymptomatic patients was noted (Figure 4E. r =
-31; p = 0.03) but not in the symptomatic ones (Figure 4F.
r = 0.05; p = 0.88). Thus, besides differing in anti-SGS
antibody levels, asymptomatic and symptomatic P. vivax-
infected individuals also differ in their cytokine balance.
Cytokine profile may be implicated in minimizing P. vivax
immunopathology, as individuals with asymptomatic
infection presented lower IFN-γ/IL-10 ratio compared to
symptomatic patients (Figure 4G; p < 0.0001). As previ-
ously described [3] and also presented in this work (Table
2), asymptomatic parasitaemia directly correlated to
increased age and is more frequently observed in people
residing for a long time in malaria endemic areas. In these
regions, an extensive exposure to mosquito bites occurs
over time. Malaria infection rates in these insects usually
range from below 0.1% to 10% [23,24]. Consequently,
each inhabitant is exposed to much more uninfected mos-
quitoes than infected ones. The recurrent exposure to
mosquito bites or also to the Plasmodium may lead to a
modification on the host immune response. It has been
shown that repeated exposure to mosquito bites induces a
Th1 profile in experimental models, leading to increased
resistance to Plasmodium  transmission [11]. This work
shows that chronic exposure to An. darlingi bites relates to
a reduction in the IFN-γ/IL-10 ratio not implying any
causal relationship. On the other hand, as malaria clinical
syndromes result from inadequate activation of pro-
inflammatory cascades, oxidative stress and disturbs in
immune regulation [25], this study hypothesizes that peo-
ple residing in malaria endemic areas repeatedly exposed
to uninfected mosquito bites over many years develop an
Anti-saliva IgG serum levels from non-infected individuals and  asymptomatic malaria patients Figure 2
Anti-saliva IgG serum levels from non-infected indi-
viduals and asymptomatic malaria patients. Serums 
were collected from non-infected individuals (n = 80), and 
from patients with asymptomatic (n = 50) P. vivax infection. 
An ELISA test was performed to assess the IgG anti-An. dar-
lingi SGS. (A) Box plot graphs of IgG serum levels from non-
infected individuals and from patients with asymptomatic P. 
vivax infection. Lines of the boxes represent 75th percentile, 
median and 25th percentile of the individual average OD val-
ues; whiskers represent the maximum and minimum values. 
Differences between groups were tested using Mann-Whit-
ney test. (B) ROC curve evaluating the threshold value of 
anti-SGS that separates non-infected individuals from asymp-
tomatic P. vivax infection. Area under curve (AUC) calcu-
lated, together with the cut off value, which presents the 
higher likelihood ratio, and p values are plotted.
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Serum Anti-An. darlingi SGS levels in patients with different  clinical spectrum of P. vivax infection Figure 3
Serum Anti-An. darlingi SGS levels in patients with 
different clinical spectrum of P. vivax infection. Serums 
were collected from volunteers with asymptomatic P. vivax 
infection (n = 50) and from patients with symptomatic infec-
tion (n = 74). An ELISA test was performed to assess the IgG 
anti-An. darlingi SGS. Box plot graph, with lines of the boxes 
representing 75th percentile, median and 25th percentile of 
the individual average OD values; whiskers represent the 
maximum and minimum values. Differences between groups 
were tested using Mann-Whitney test; p value is plotted.
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Correlation between cytokine plasma levels and anti-saliva IgG titers Figure 4
Correlation between cytokine plasma levels and anti-saliva IgG titers. (A) IL-10 vs. anti-SGS (OD), (B) IFN-γ, and (C) 
IFN-γ/IL-10 ratio vs. anti-SGS in patients with asymptomatic P. vivax infection. (D) IL-10 vs. anti-SGS (OD), (E) IFN-γ, and (F) 
IFN-γ/IL-10 ratio vs. anti-SGS in patients with symptomatic P. vivax infection. Fine Lowess curves are shown in (C) and (F) to 
evidence the trend of the data. Non-parametric Spearman test was used to verify statistical significance. (G) Comparison of 
IFN-γ/IL-10 ratio between volunteers with asymptomatic or symptomatic P. vivax infection. Mann-Whitney test was used to 
estimate the significance. P values, together with r values, are plotted in each graph.
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efficient anti-saliva immune response, in which IL-10 may
favor the production of specific antibodies. The neutrali-
zation of some vector salivary proteins may create micro-
environment alterations in the site of mosquito bites that
might ultimately affect the transmission of malaria.
Another possibility is that mosquito bites, and also the
continued exposure to Plasmodium, induce higher produc-
tion of IL-10, which may reduce intense pro-inflamma-
tory responses and the immunopathology of the
infection. This study does not present experimental basis
to indicate any direct effect of antibodies against An. dar-
lingi  salivary components on clinical status of P. vivax
infected individuals. An important limitation regarding
the use of anti-SGS levels as a marker for malaria infection
is represented by the considerable variation of malaria
transmission among different areas and also from season
to season. This would make mandatory the establishment
of appropriate anti-SGS cut-off level before using it as a
marker for malaria. Nevertheless, once the cut-off levels
are defined, the measurement of anti-SGS could serve as a
very sensible indicator of this disease.
Conclusion
Through the estimation of serum anti-An. darlingi saliva
antibody levels, it is possible to infer the probable P. vivax
infection status as marker of disease severity of an individ-
ual from the Amazon endemic area. Moreover, this study
also suggests that the clinical immunity against P. vivax
could be associated to a specific humoral response against
the salivary components. As previously described to other
vector-borne diseases, such as leishmaniasis, the detection
of increased levels of anti-vector saliva could be pointed as
an epidemiological marker of infection and also as a suit-
able indicator of clinical immunity in endemic regions.
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